Objectives: To assess the real-world tolerability of teriflunomide in multiple sclerosis (MS)
patients from a large Canadian MS Centre of Care to determine whether previously treated …

Background The demographics and management of patients with multiple sclerosis (MS)
differ across geographical regions, but it is unclear whether/how these differences affect …

Objective To identify baseline factors associated with disease activity in patients with
relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods This …

OBJECTIVE: To report long-term efficacy and safety data from patients treated with
teriflunomide for≤ 12 years. BACKGROUND: Teriflunomide is a once-daily oral …

Background: Evidence suggests that efficacy and safety of disease-modifying treatments for
multiple sclerosis may differ with age. We evaluate efficacy and safety of teriflunomide …

Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once
daily) in association with age and pre-treatment in unselected MS patients. Methods …

Background Teriflunomide, a once-daily oral immunomodulator for the treatment of
relapsing-remitting multiple sclerosis, has demonstrated consistent efficacy on clinical and …

Background In the phase 3 TOWER core study (NCT00751881), the efficacy and safety of
teriflunomide compared with placebo were demonstrated in patients with relapsing forms of …

Objectives Teriflunomide 14 mg is a once‐daily oral disease‐modifying treatment for
relapsing‐remitting multiple sclerosis. We examined adverse event (AE) profile and efficacy …

Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing
forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting …